Research Topics
Species | Hiroaki WakimotoSummaryAffiliation: Massachusetts General Hospital Country: USA Publications
| Collaborators
|
Detail Information
Publications
Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectorsHiroaki Wakimoto
Molecular Neurosurgery Laboratory, Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital, Boston, MA 02114, USA
Cancer Res 69:3472-81. 2009..This is important for designing new oHSV vectors and clinical trials. Moreover, the new glioma models described in this study provide powerful tools for testing experimental therapeutics and studying invasion and angiogenesis...- Maintenance of primary tumor phenotype and genotype in glioblastoma stem cellsHiroaki Wakimoto
Department of Neurosurgery, Massachusetts General Hospital, Boston, MA 02114, USA
Neuro Oncol 14:132-44. 2012..These studies highlight the value of GSCs for preclinical modeling of clinically relevant, patient-specific GBM and, thus, pave the way for testing novel anti-GSC/GBM agents for personalized therapy... - Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cellsRyuichi Kanai
Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
J Natl Cancer Inst 104:42-55. 2012.... - A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cellsRyuichi Kanai
Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
Clin Cancer Res 17:3686-96. 2011..One approach to enhance oHSV efficacy is by combination with other therapeutic modalities... 
Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cellsDonatella Sgubin
Department of Neurosurgery, Brain Tumor Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
Stem Cells Transl Med 1:322-32. 2012..These findings suggest that oHSV G47Δ represents a promising therapeutic strategy to target and kill GSCs, not only in normoxic areas of GBM but also within the hypoxic niche...- Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effectsJeroen A J M van de Water
Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA
Proc Natl Acad Sci U S A 109:16642-7. 2012..This study demonstrates the efficacy of SC-based EGFR targeted therapy in GBMs and provides a unique approach with clinical implications... - Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumorsRyuichi Kanai
Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
J Virol 86:4420-31. 2012..Thus, Δ68H-6 represents a new oHSV vector that is safe and effective against a variety of brain tumor models... - Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenograftsTooba A Cheema
Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital, Boston, USA
Clin Cancer Res 17:7383-93. 2011..We investigate a novel combinatorial approach of low-dose etoposide with an oncolytic HSV to enhance antitumor activity and limit drug toxicity... - Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumorsKaoru Tamura
Molecular Neurotherapy and Imaging Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02129, USA
Mol Ther 21:68-77. 2013..This study sheds new light on the mechanism by which oHSV and TRAIL function in concert to overcome therapeutic-resistance, and provides an oncolytic virus based platform to target a broad spectrum of different cancer types... - Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant gliomaZachary Barnard
Simches Brain Tumor Research Laboratories, Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
Neurosurgery 71:741-8; discussion 748. 2012.... - Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?Ryuichi Kanai
Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA
Future Oncol 6:619-34. 2010..In this article, we will discuss the recent progress of these combinatorial strategies between virotherapy and chemotherapy and future directions... - Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapyLaura S Sasportas
Molecular Neurotherapy and Imaging Laboratory, Department of Radiology, Massachusetts General Hospital, Harvard Medical School Boston, MA 02114, USA
Proc Natl Acad Sci U S A 106:4822-7. 2009..This study demonstrates the efficacy of diagnostic and therapeutic MSC in preclinical glioma models and forms the basis for developing stem cell-based therapies for different cancers... - Directed evolution of adeno-associated virus for glioma cell transductionCasey A Maguire
Department of Neurology, Massachusetts General Hospital, and Neuroscience Program, Harvard Medical School, Boston, MA, USA
J Neurooncol 96:337-47. 2010.... 
Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeuticsTa Chiang Liu
Molecular Neurosurgery Laboratory, Brain Tumor Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
Clin Cancer Res 13:5897-902. 2007..We hypothesized that Us3 mutants, whose replication would be inhibited by apoptosis in normal cells, would be selective for tumor cells...- A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma modelsTugba Bagci-Onder
Molecular Neurotherapy and Imaging Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
Cancer Res 71:154-63. 2011..Our findings offer a preclinical rationale for application of mechanism-based systemically delivered antiproliferative agents and novel stem cell-based proapoptotic therapies to improve treatment of malignant gliomas... - Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replicationBrent J Passer
Departments of Neurosurgery and Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
Cancer Res 70:3890-5. 2010..Our results indicate that ENT1 antagonists augment oHSV replication in tumor cells by increasing cellular ribonucleoside activity... - PTEN decreases in vivo vascularization of experimental gliomas in spite of proangiogenic stimuliTatsuya Abe
Molecular Neuro-Oncology Laboratories, Neurosurgery Service, Center for Molecular Imaging Research, Massachusetts General Hospital, Harvard Medical School, Charlestown 02129, USA
Cancer Res 63:2300-5. 2003..Taken in combination, these results provide strong evidence of PTEN/MMAC's role in regulating glioma angiogenesis even in the presence of strong proangiogenic signals provided by constitutive EGFR activation or p53 inactivation... - Intra-arterial delivery of p53-containing adenoviral vector into experimental brain tumorsTatsuya Abe
Molecular Neuro-Oncology Laboratories, Neurosurgery Service, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA
Cancer Gene Ther 9:228-35. 2002..These findings indicate that intra-arterial administration of adenoviral vectors containing p53 is efficient and can result in changes in tumor size, but that long-term control of tumor growth may require multiple adenoviral treatments...